ТАКТИКА ВЕДЕНИЯ АСЦИТА У ПАЦИЕНТОВ С ЦИРРОЗОМ ПЕЧЕНИ
https://doi.org/10.51523/2708-6011.2012-9-3-6
Аннотация
Список литературы
1. Wong, F. Management of ascites in cirrhosis / F. Wong // J. Gastroenterol. Hepatol. - 2012. -Vol. 27. -P. 11-20.
2. D’Amico, G. Natural history andprognostic indicators of survival in cirrhosis: a systematic review of118 studies / G. D’Amico, G. Garcia-Tsao, L. Pagliaro // J. Hepatol. - 2006. - Vol. 44. - Р. 217-231.
3. Natural history of patients hospitalized for management of cirrhotic ascites / R. Planas [et al.] // Clin. Gastroenterol. Hepatol. - 2006. - Vol. 4. - Р. 1385-1394.
4. Guevara, M. Hepatorenal syndrome / M. Guevara, V. Arroyo // Expert Opin. Pharmacother. - 2011. - Vol. 12. - Р. 1405-1417.
5. Cárdenas, A. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites / A. Cárdenas, V. Arroyo // Best Pract Res Clin. Endocrinol. Metab. - 2003. - Vol. 17. - Р. 607-622.
6. The management of ascites - report on the consensus conference of the International Ascites Club / K. P. Moore [et al.] // Hepatology. - 2003. - Vol. 38. - Р. 258-266.
7. Refractory ascites, pathogenesis, definition, and therapy of a severe complication in cirrhotic patients / F. Salerno [et al.] // Liver Int. - 2010. - Vol. 30. - Р. 937-947.
8. Runyon, B. A. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update / B. A. Runyon // Hepatology. - 2009. - Vol. 49. - Р. 2087-2107.
9. Leung, W. Medical management of ascites/ W. Leung, F. Wong // Expert Opin. Pharmacother. - 2011. - Vol. 12. - P. 1269-1283.
10. Wong, F. Drug insight: the role of albumin in the management ofchronic liver disease / F. Wong // Nat. Clin. Pract. Gastroenterol. Hepatol. - 2007. - Vol. 4. - Р. 43-51.
11. Long-term albumininfusion improves survival in patients with cirrhosis and ascites: anunblinded randomized trial / R. G. Romanelli [et al.] // World J. Gastroenterol. - 2006. - Vol. 12. - Р. 1403-1407.
12. The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: a multi-center randomized placebo controlled trial / F. Wong [et al.] // Hepatology. - 2003. - Vol. 37. - Р. 182-191.
13. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia / R. W. Schrier [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - Р. 2099-2112.
14. Ginès, P. Effects of Satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in patients with cirrhosis and hyponatremia / P. Ginès [et al.] // Hepatology. - 2008. - Vol. 48. - Р. 204-213.
15. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity / F. Wong, [et al.] // Gut. - 2011 (in press).
16. Effects of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites / F. Nevens [et al.] // J. Hepatol. - 2009. - Vol. 50. - Р. 76.
17. Colombato, L. The role of transjugular intrahepatic porto-systemicshunt (TIPS) in the management of portal hypertension / L. Colombato // J. Clin. Gastroenterol. - 2007. - Vol. 41. - Р. 344-351.
18. Transjugularintrahepatic portosystemic shunt for refractory ascites, ameta-analysis of individual patient data / F. Salerno [et al.] // Gastroenterology. - 2007. - Vol. 133. - Р. 825-834.
Рецензия
Для цитирования:
Малаева Е.Г. ТАКТИКА ВЕДЕНИЯ АСЦИТА У ПАЦИЕНТОВ С ЦИРРОЗОМ ПЕЧЕНИ. Проблемы здоровья и экологии. 2012;(3):28-35. https://doi.org/10.51523/2708-6011.2012-9-3-6
For citation:
Malaeva E.G. MANAGEMENT OF ASCITES IN CIRRHOSIS. Health and Ecology Issues. 2012;(3):28-35. (In Russ.) https://doi.org/10.51523/2708-6011.2012-9-3-6